Abstract
A clinical trial undertaken at Surgical Department No. I of the Institute included the data on 569 cases of stage I-III breast cancer treated in 1985-1989. Adjuvant CMF or TMF chemotherapy failed to improved 5-year survival (chemotherapy 2--285.2%, no chemotherapy--84.8%) in patients with stage I-IIa (TO-2NOMO) disease. Adjuvant treatment with adrioblastin proved superior over CMF and TMF in terms of 5-year overall survival in patients with stage III (T3NO-IMO; TO-3N2MO) cancer (71.0 and 55.0%, respectively).
Publication types
-
Clinical Trial
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Chemotherapy, Adjuvant
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Mastectomy, Radical
-
Methotrexate / administration & dosage
-
Middle Aged
-
Neoplasm Staging
-
Preoperative Care
-
Russia / epidemiology
-
Thiotepa / administration & dosage
-
Time Factors
Substances
-
Cyclophosphamide
-
Thiotepa
-
Fluorouracil
-
Methotrexate